Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6386MR)

This product GTTS-WQ6386MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6386MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5004MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ11777MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ9086MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ3790MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ12480MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ3568MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ15876MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ4497MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-931699
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW